Last reviewed · How we verify
octreotide FluidCrystal® injection depot
octreotide FluidCrystal® injection depot is a Small molecule drug developed by Camurus AB. It is currently in Phase 2 development. Also known as: CAM2029.
At a glance
| Generic name | octreotide FluidCrystal® injection depot |
|---|---|
| Also known as | CAM2029 |
| Sponsor | Camurus AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- octreotide FluidCrystal® injection depot CI brief — competitive landscape report
- octreotide FluidCrystal® injection depot updates RSS · CI watch RSS
- Camurus AB portfolio CI
Frequently asked questions about octreotide FluidCrystal® injection depot
What is octreotide FluidCrystal® injection depot?
octreotide FluidCrystal® injection depot is a Small molecule drug developed by Camurus AB.
Who makes octreotide FluidCrystal® injection depot?
octreotide FluidCrystal® injection depot is developed by Camurus AB (see full Camurus AB pipeline at /company/camurus-ab).
Is octreotide FluidCrystal® injection depot also known as anything else?
octreotide FluidCrystal® injection depot is also known as CAM2029.
What development phase is octreotide FluidCrystal® injection depot in?
octreotide FluidCrystal® injection depot is in Phase 2.
Related
- Manufacturer: Camurus AB — full pipeline
- Also known as: CAM2029
- Compare: octreotide FluidCrystal® injection depot vs similar drugs
- Pricing: octreotide FluidCrystal® injection depot cost, discount & access